Progentec Diagnostics Completes Second Funding Round

healthcareProgentec Diagnostics, Inc., an Oklahoma City-based developer of technological innovations in the field of diagnostics, completed a second round of funding.

The round was co-led by i2E and Chicago-based OCA Ventures, with participation from NMC Lifesciences.

The company intends to use the funds to bring its tool for identifying Lupus flare ups and a biomarker-based disease-activity index closer to commercialization.

Technology created by the Oklahoma Medical Research Foundation (OMRF) is at the core of the platform being developed by Progentec.

Led by Mohan Purushothaman, CEO, Progentec also announced the acquisition of LupusCorner, a patient-empowerment platform for people with systemic lupus erythematosus (SLE) and lupus nephritis. By integrating LupusCorner’s technology platform and data insights, Progentec aims to develop a first-in-class lupus-management platform.
The founders of LupusCorner, Arif Sorathia and Brett Adelman, have joined Progentec and will help lead technology, outreach and growth initiatives.
Progentec’s technologies include accurate bio-marker based tests to diagnose disease before symptoms begin to show, as well as tests to monitor and predict disease activity levels in Lupus.



Join the discussion